#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Carine Leclercq Email
Administrative & Office Manager, DPO . OSIVAX
Lyon,
LocationPrimary Email
How to contact Carine Leclercq
Join and see Carine's contact info for free!Current Roles
Employees:
63Revenue:
$9.8MAbout
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T-cell responses Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, in order to accelerate the development of oligoDOM® technology platform oligoDOM® technology platform capitalizes on: - More than 12 years of R&D on a breakthrough approach to induce CD8 T-cell immunity - Clinical package developed by OSIVAX on a universal influenza vaccine candidate - Clinical and preclinical data generated by leading independent teams in Europe (Oxford University, DKFZ / Heidelberg University, Inserm / CNRS...) Osivax lead program is a game-changing universal influenza vaccine - Leveraging oligoDOM® technology, Osivax's team is developing a standalone recombinant vaccine to prevent moderate to severe cases of seasonal and pandemic influenza - This oligoDOM®-based universal influenza vaccine induces powerful CD8 T-cell immune responses against the highly conserved flu NucleoProtein (NP) and won't require annual updates as NP is a highly conserved antigen - The aim of this universal Influenza vaccine is to provide greater than 70% protection from morbidity and mortality caused by current and future A- and B-strain influenza viruses (1) - Osivax universal vaccine program is currently in phase I clinical trial, actively preparing a phase IIa Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertises Osivax is based in Lyon (France) and Liège (Belgium), the two clusters of vaccine R&D in Europe. Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigensOSIVAX Address
70, Rue Saint-Jean-de-DieuLyon, null